Katherine N Cahill1, Pingsheng Wu2, Ginger L Milne3, Taneem Amin2, Joseph Singer4, Katherine Murphy4, Erin Lewis4, Deborah Gapko4, Joshua A Boyce5, Katherine M Buchheit5, Tanya M Laidlaw5. 1. Department of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tenn. Electronic address: Katherine.cahill@vumc.org. 2. Department of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tenn. 3. Department of Pharmacology, Vanderbilt University, Nashville, Tenn. 4. Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Mass. 5. Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Mass; Jeff and Penny Vinik Center for Translational Immunology Research, Boston, Mass; Harvard Medical School, Boston, Mass.
Abstract
BACKGROUND: Patients with aspirin-exacerbated respiratory disease can experience severe reactions during aspirin challenge that are associated with high levels of mast cell mediators. The tissue source and clinical factors contributing to systemic mediator levels are unknown. OBJECTIVE: We sought to determine the concordance between respiratory tract and systemic inflammatory mediator levels and identify clinical factors associated with these mediators. METHODS: We performed an oral aspirin challenge in 30 subjects with aspirin-exacerbated respiratory disease. Respiratory symptoms and function, nasal mucosal fluid, blood, and urine were collected at baseline, at the onset of a respiratory reaction, and over a 3-hour observation period. Changes in nasal and systemic mediator levels were compared. RESULTS: Neither tryptase nor leukotriene E4 levels in nasal fluid correlated with serum tryptase or urinary leukotriene E4 levels at baseline or during reactions. We observed no association between the baseline or aspirin-induced change in nasal versus urinary leukotriene E4 and serum tryptase levels. Body mass index inversely correlated with baseline and aspirin-induced urinary leukotriene E4, prostaglandin D2 metabolite, and serum tryptase levels, as well as with aspirin-induced symptoms and respiratory function, but not with nasal mediators. CONCLUSIONS: The levels of nasal and systemic aspirin-induced mast cell products are discordant in aspirin-exacerbated respiratory disease. Systemically detected levels are likely derived from mast cells outside of the sinonasal cavity and do not accurately reflect upper respiratory tract production. Increased body mass index decreases systemic mast cell mediator production and reaction severity, supporting a contribution of metabolic regulation in aspirin-induced systemic reactions.
BACKGROUND: Patients with aspirin-exacerbated respiratory disease can experience severe reactions during aspirin challenge that are associated with high levels of mast cell mediators. The tissue source and clinical factors contributing to systemic mediator levels are unknown. OBJECTIVE: We sought to determine the concordance between respiratory tract and systemic inflammatory mediator levels and identify clinical factors associated with these mediators. METHODS: We performed an oral aspirin challenge in 30 subjects with aspirin-exacerbated respiratory disease. Respiratory symptoms and function, nasal mucosal fluid, blood, and urine were collected at baseline, at the onset of a respiratory reaction, and over a 3-hour observation period. Changes in nasal and systemic mediator levels were compared. RESULTS: Neither tryptase nor leukotriene E4 levels in nasal fluid correlated with serum tryptase or urinary leukotriene E4 levels at baseline or during reactions. We observed no association between the baseline or aspirin-induced change in nasal versus urinary leukotriene E4 and serum tryptase levels. Body mass index inversely correlated with baseline and aspirin-induced urinary leukotriene E4, prostaglandin D2 metabolite, and serum tryptase levels, as well as with aspirin-induced symptoms and respiratory function, but not with nasal mediators. CONCLUSIONS: The levels of nasal and systemic aspirin-induced mast cell products are discordant in aspirin-exacerbated respiratory disease. Systemically detected levels are likely derived from mast cells outside of the sinonasal cavity and do not accurately reflect upper respiratory tract production. Increased body mass index decreases systemic mast cell mediator production and reaction severity, supporting a contribution of metabolic regulation in aspirin-induced systemic reactions.
Authors: Zachary J Ward; Sara N Bleich; Angie L Cradock; Jessica L Barrett; Catherine M Giles; Chasmine Flax; Michael W Long; Steven L Gortmaker Journal: N Engl J Med Date: 2019-12-19 Impact factor: 91.245
Authors: L B Schwartz; T R Bradford; C Rouse; A M Irani; G Rasp; J K Van der Zwan; P W Van der Linden Journal: J Clin Immunol Date: 1994-05 Impact factor: 8.317
Authors: Andrew White; Elizabeth Ludington; Purvi Mehra; Donald D Stevenson; Ronald A Simon Journal: Ann Allergy Asthma Immunol Date: 2006-11 Impact factor: 6.347
Authors: Peter Mancuso; Claudio Canetti; Andrew Gottschalk; Patricia K Tithof; Marc Peters-Golden Journal: Am J Physiol Lung Cell Mol Physiol Date: 2004-05-14 Impact factor: 5.464